Esperion Therapeutics Inc. [ESPR] stock Downgrade by Credit Suisse analyst, price target now $6

Esperion Therapeutics Inc. [NASDAQ: ESPR] surged by $0.03 during the normal trading session on Thursday and reaching a high of $6.05 during the day while it closed the day at $5.85. The company report on December 13, 2022 that Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4).

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

Esperion Therapeutics Inc. stock has also loss -5.34% of its value over the past 7 days. However, ESPR stock has declined by -16.55% in the 3 months of the year. Over the past six months meanwhile, it has gained 18.90% and gained 17.00% year-on date.

The market cap for ESPR stock reached $523.40 million, with 73.68 million shares outstanding and 73.15 million shares in the current float. Compared to the average trading volume of 1.69M shares, ESPR reached a trading volume of 2812027 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Esperion Therapeutics Inc. [ESPR]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ESPR shares is $11.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ESPR stock is a recommendation set at 2.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Credit Suisse have made an estimate for Esperion Therapeutics Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on August 03, 2022. The new note on the price target was released on May 05, 2022, representing the official price target for Esperion Therapeutics Inc. stock. Previously, the target price had yet another raise to $22, while H.C. Wainwright analysts kept a Buy rating on ESPR stock. On October 19, 2021, analysts decreased their price target for ESPR shares from 28 to 11.

The Average True Range (ATR) for Esperion Therapeutics Inc. is set at 0.58, with the Price to Sales ratio for ESPR stock in the period of the last 12 months amounting to 7.26.

ESPR stock trade performance evaluation

Esperion Therapeutics Inc. [ESPR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.34. With this latest performance, ESPR shares dropped by -19.86% in over the last four-week period, additionally plugging by 18.90% over the last 6 months – not to mention a rise of 9.35% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ESPR stock in for the last two-week period is set at 38.75, with the RSI for the last a single of trading hit 38.87, and the three-weeks RSI is set at 39.96 for Esperion Therapeutics Inc. [ESPR]. The present Moving Average for the last 50 days of trading for this stock 7.38, while it was recorded at 5.55 for the last single week of trading, and 6.41 for the last 200 days.

Esperion Therapeutics Inc. [ESPR]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Esperion Therapeutics Inc. [ESPR] shares currently have an operating margin of -289.02 and a Gross Margin at +81.10. Esperion Therapeutics Inc.’s Net Margin is presently recorded at -343.04.

Esperion Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.80 and a Current Ratio set at 3.20.

Earnings per share (EPS) analysis for Esperion Therapeutics Inc. [ESPR] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ESPR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Esperion Therapeutics Inc. go to 16.90%.

Esperion Therapeutics Inc. [ESPR]: Insider Ownership positions

There are presently around $371 million, or 87.80% of ESPR stock, in the hands of institutional investors. The top three institutional holders of ESPR stocks are: WASATCH ADVISORS INC with ownership of 7,463,016, which is approximately -1.1% of the company’s market cap and around 0.50% of the total institutional ownership; DEEP TRACK CAPITAL, LP, holding 5,636,587 shares of the stock with an approximate value of $32.97 million in ESPR stocks shares; and BLACKROCK INC., currently with $26.67 million in ESPR stock with ownership of nearly 6.157% of the company’s market capitalization.

Positions in Esperion Therapeutics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 81 institutional holders increased their position in Esperion Therapeutics Inc. [NASDAQ:ESPR] by around 12,059,105 shares. Additionally, 54 investors decreased positions by around 4,087,996 shares, while 27 investors held positions by with 47,303,719 shares. The mentioned changes placed institutional holdings at 63,450,820 shares, according to the latest SEC report filing. ESPR stock had 22 new institutional investments in for a total of 2,703,142 shares, while 12 institutional investors sold positions of 312,119 shares during the same period.


Please enter your comment!
Please enter your name here